Clinical trials: Clinical Sepsis
COVID-19, Hypoxia
Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation
Previous research has shown that high dose intravenous vitamin C (HDIVC) may benefit patients with sepsis, acute lung injury (ALI), and the acute respiratory distress syndrome (ARDS).
- Trial name
- AVoCaDO (NCT04357782)
- Testing
- L-ascorbic acid
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Hunter Holmes Mcguire Veteran Affairs Medical Center
Sepsis
Effects of Code Sepsis Implementation on Emergency Department (ED) Sepsis Care
Sepsis is a life-threatening complication of infection that can be difficult to recognize and treat promptly. Timely administration of antibiotics for emergency department (ED) patients with sepsis is challenging.
- Trial name
- Code Sepsis (NCT04148989)
- Testing
- Code Sepsis protocol (full implementation)
- Where
- 3 sites in United States
- Volunteers
- 180,402 people
- Sponsor
- Intermountain Health Care, Inc.
Healthy Volunteer Safety Study
AB103 Peptide Antagonist in Healthy Volunteers
The primary objective of this study is to establish the safety profile and maximum tolerated dose (MTD) of AB103 given as a single intravenous (IV) infusion in healthy volunteers.
- Trial name
- NCT01166984
- Testing
- AB103
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Atox Bio Ltd
Clostridia Difficile Colitis, Clostridium; Sepsis
Comparing the Effectiveness of IV Bezlotoxumab Versus Placebo in Decreasing Morbidity and Mortality in Patients With Fulminant C. Diff Requiring Surgery.
A new medication, Bezlotoxumab, has been approved for treatment of recurrent Clostridium difficile diarrhea by the U.S. Food and Drug Administration. The way this new medication works, is by binding the toxin produced by C.
- Trial name
- NCT03756454
- Testing
- Bezlotoxumab, Normal Saline
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Ohio State University
Sepsis, Necrotising Enterocolitis Neonatal
Integrated Predictive Monitoring for Sepsis and Necrotizing Enterocolitis
Behind the scenes pilot trial in the computer lab involving chart review to use neonatal intensive care unit data to create computer models predicting sepsis and necrotizing enterocolitis in very small premature infants
- Trial name
- PREMO (K) (NCT07254559)
- Testing
- No Intervention: Observational Cohort
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- University of Virginia
Bacteremia, Sepsis
Rapid Blood Culture Identification Panel in Pediatric Patients in Guatemala
The purpose of this study is to assess the clinical impact of a rapid multiplex PCR blood culture identification panel on time to optimal antimicrobial therapy when compared to conventional microbiological culture methods in…
- Trial name
- NCT05314816
- Testing
- Blood culture identification panel
- Where
- Guatemala
- Volunteers
- 479 people
- Sponsor
- University of Colorado, Denver
Staphylococcal Infection
A Study of MK-3009 in Japanese Patients With Skin or Blood Stream Infections Caused by Methicillin-resistant Staphylococcus Aureus (MK-3009-002)
The study investigates the efficacy and safety of MK-3009 in participants with skin infections, septicemia and right-sided infective endocarditis (RIE) caused by methicillin-resistant Staphylococcus aureus (MRSA).
- Trial name
- NCT00770341
- Testing
- Daptomycin 4 mg/kg, Comparator: vancomycin, Daptomycin 6 mg/kg
- Volunteers
- 122 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI)
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
This study is designed to provide evidence of efficacy of cefiderocol in the treatment of serious infections in adult patients caused by carbapenem-resistant Gram-negative pathogens.
- Conditions
- Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI), Hospital Acquired Pneumonia (HAP), Complicated Urinary Tract Infection (cUTI)
- Trial name
- CREDIBLE - CR (NCT02714595)
- Testing
- Cefiderocol, Best Available Therapy
- Where
- 85 sites in United States, Brazil and 14 more
- Volunteers
- 152 people
- Sponsor
- Shionogi
Gram-Negative Bacterial Infections, Sepsis
The Effects of Polymyxin-B Protects on Sepsis Induced Kidney Dysfunction: a Randomized Clinical Trial
Aim of the study is to verify whether Polymyxin-B hemoperfusion protects from renal dysfunction in patients with severe sepsis from gram negative infection.
- Trial name
- NCT00490477
- Testing
- Polymyxin -B fiber hemoperfusion system
- Where
- Italy
- Volunteers
- 16 people
- Sponsor
- University of Turin, Italy
Antibiotic Resistant Infection, Nosocomial Infection
Inulin for Infections in the Intensive Care Unit
Normal gut bacteria prevent colonization and subsequent infection with MDR organisms (MDROs) through competition for resources and other mechanisms.
- Conditions
- Antibiotic Resistant Infection, Nosocomial Infection, Pathogen Transmission, Nutrition Disorders
- Trial name
- NCT03865706
- Testing
- Inulin Oral Suspension, Broad-spectrum antibiotics
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Columbia University
MRSA Bacteremia
A Phase 2a Study, Effect of Vancomycin With vs Without Delpazolid (LCB01-0371) in Patients With MRSA Bacteremia
The objectives of this study is to exploratory whether Vancomycin + Delpazolid is more effective to the standard of treatment (Vancomycin)/ for hospitalized adults with MRSA bacteraemia.
- Trial name
- NCT05225558
- Testing
- Delpazolid, Vancomycin
- Where
- 6 sites in South Korea
- Volunteers
- 40 people
- Sponsor
- LigaChem Biosciences, Inc.
Shock, Septic
COMPACT 2 - COMbining Plasma-filtration and Adsorption Clinical Trial 2
The study objective is to clarify whether the application of high doses CPFA (coupled plasma-filtration adsorption) in addition to the current clinical practice is able to reduce hospital mortality in septic shock patients in…
- Trial name
- COMPACT-2 (NCT01639664)
- Testing
- High doses CPFA
- Where
- 13 sites in Italy
- Volunteers
- 115 people
- Sponsor
- Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva
Sepsis
Implementation and Effectiveness of Engagement and Collaborative Management to Proactively Advance Sepsis Survivorship
The purpose of this study is to evaluate if implementation of the Sepsis Transition and Recovery (STAR) program within a large healthcare system will improve outcomes for high-risk patients with suspected sepsis, while…
- Trial name
- ENCOMPASS (NCT04495946)
- Testing
- Sepsis Transition and Recovery (STAR) program, Usual care
- Where
- United States
- Volunteers
- 3,894 people
- Sponsor
- Wake Forest University Health Sciences
Toxic Shock Syndrome
Clinical Trial of the BioMed rTSST-1 Variant Vaccine in Healthy Adults
Toxic Shock Syndrome (TSS) is a severe condition with high morbidity and mortality from the hosts overwhelming inflammatory response and cytokine storm. Staphylococcal superantigen toxins are the main causative agents.
- Trial name
- NCT02814708
- Testing
- rTSST-1v
- Where
- Austria
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Biomedizinische Forschungs gmbH
Septic Shock
Treatment of Patients With Early Septic Shock and Bio-Adrenomedullin(ADM) Concentration > 70 pg/ml With ADRECIZUMAB
This is a double-blind, placebo-controlled, randomized, multicenter proof of concept and dose-finding phase II study using two doses of ADRECIZUMAB in patients with early septic shock and a bio-ADM plasma concentration at…
- Trial name
- AdrenOSS-2 (NCT03085758)
- Testing
- Adrecizumab
- Where
- 30 sites in Belgium, France and 2 more
- Volunteers
- 301 people
- Sponsor
- Adrenomed AG